AtriCure price target lowered to $52 from $58 at BTIG

BTIG lowered the firm’s price target on AtriCure (ATRC) to $52 from $58 and keeps a Buy rating on the shares. The company’s Q1 saw particularly strong sales from U.S. Appendage Management and the Cryosphere products in U.S. Pain Management, but much of this outperformance was offset by more pronounced weakness in the U.S. Minimally Invasive Ablation segment, as the Convergent procedure continued to face pressure from the distraction of pulsed field ablation adoption, the analyst tells investors in a research note.